Chartoreg

Composition:
Each tablet contain: or 40 mg or 80 mg telmisartan as active ingredient.

 

Indications and usage:

  1. Hypertension:

Chartoreg is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

 

  1. Cardiovascular Risk Reduction:

Chartoreg is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.

 

Dosage and administration:

  • Hypertension: 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg [see Clinical Studies].

            Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally             attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg             Chartoreg is required, a diuretic may be added.

            No initial dosage adjustment is necessary for elderly patients or patients with renal impairment,             including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood             pressure should be closely monitored.

            Chartoreg tablets may be administered with other antihypertensive agents.

            Chartoreg tablets may be administered with or without food.

  • Cardiovascular Risk Reduction: 80 mg once a day and can be administered with or without food.

            When initiating Chartoreg therapy for cardiovascular risk reduction, monitoring of blood pressure is             recommended, and if appropriate, adjustment of medications that lower blood pressure may be             necessary.

 

Contraindications:

            The concomitant use of telmisartan with aliskiren-containg products is contraindicated in patients         with diabetes mellitus or renal impairment (GFR< 60ml/min/1.73m2)

 

 

Clinical pharmacology:

  • Mechanis m of Action:

            Block renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I,. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovasculr regulation.

Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure.

 

Package

Carton box containing 1, 2, 3 or 4 (AL/AL) strips each of 7 tablets + inner leaflet.

Keep out of reach of children.